Market Place
Sourcing Support
Exicure, Inc. Receives Extension from Nasdaq Hearings Panel
18 Sep 2024 //
BUSINESSWIRE
Exicure, Inc. Announces 1-for-5 Reverse Stock Split
26 Aug 2024 //
BUSINESSWIRE
Exicure Announces Special Meeting Adjournment And Reconvening Information
19 Aug 2024 //
BUSINESSWIRE
Exicure Adjourns Special Meeting And Provides Reconvened Meeting Details
15 Aug 2024 //
BUSINESSWIRE
Exicure, Inc. Reports Second Quarter 2024 Financial Results
13 Aug 2024 //
BUSINESSWIRE
Exicure, Inc. Recruits Head of Corporate Development and Bioinformatics
08 Aug 2024 //
BUSINESSWIRE
Exicure Reports First Quarter 2024 Financial Results
17 Jun 2024 //
BUSINESSWIRE
Exicure, Inc. Reports Full Year 2023 Financial Results
07 Jun 2024 //
BUSINESSWIRE
Exicure, Inc. Reports Full Year 2023 Financial Results
06 Jun 2024 //
BUSINESSWIRE
Exicure, Inc. Reports Third Quarter 2023 Financial Results
16 May 2024 //
BUSINESSWIRE
Exicure and Bluejay Therapeutics Inc. Enter into a Patent License Agreement
05 Feb 2024 //
BUSINESSWIRE
Exicure, Inc. Announces Appointment of New CEO and CFO
23 Aug 2023 //
BUSINESSWIRE
Exicure`s CEO, CFO takes lead in search to bail out the biotech
30 May 2023 //
FIERCE BIOTECH
Exicure, Inc. Announces Support of CEO in its Exploration of Alternatives
26 May 2023 //
BUSINESSWIRE
Exicure, Inc. Announces Investment in Korean SNS Platform Cyworld
04 May 2023 //
BUSINESSWIRE
Exicure, Inc. Announces Appointment of New CEO and CFO and Changes to BOD
27 Apr 2023 //
BUSINESSWIRE
Exicure considers transaction of some kind in death spiral
28 Mar 2023 //
FIERCE BIOTECH
Exicure Reports Full Year 2022 Financial Results and Provides Corporate Update
27 Mar 2023 //
BUSINESSWIRE
Exicure Announces Termination of AbbVie and Ipsen Collaboration Agreements
15 Dec 2022 //
BUSINESSWIRE
Months after executive exodus, Exicure shaves off 66% of staff
27 Sep 2022 //
FIERCEBIOTECH
Exicure Enters Into Agreement With CBI USA for $5.4 Million Equity Financing
26 Sep 2022 //
BUSINESSWIRE
Exicure Announces Presentation at Chardan’s Annual Genetic Medicines Conference
01 Sep 2022 //
BUSINESSWIRE
Exicure, Inc. Reports Second Quarter 2022 Financial Results
15 Aug 2022 //
BUSINESSWIRE
Exicure Announces Receipt of Nasdaq Notice of One-for-Thirty Reverse Stock Split
29 Jun 2022 //
BUSINESSWIRE
Exicure Announces Leadership Transition and Changes to the Board of Directors
04 Feb 2022 //
BUSINESSWIRE
Exicure Announces $11.5 Million Registered Direct Offering Priced At-The-Market
14 Dec 2021 //
BUSINESSWIRE
Exicure: Results of Internal Investigation & Implements Strategic Actions
10 Dec 2021 //
BUSINESSWIRE
Exicure Reports Q3 2021 Financial Results and Corporate Progress
19 Nov 2021 //
BUSINESSWIRE
Exicure Files Form 12b-25
15 Nov 2021 //
BUSINESSWIRE
Exicure Provides Interim Results from Phase 1b/2 Clinical Trial of Cavrotolimod
05 Aug 2021 //
BUSINESSWIRE
Ipsen commits up to $1B to Exicure for two rare neuro assets
03 Aug 2021 //
FIERCEBIOTECH
Ipsen commits up to $1B to Exicure for two rare neuro assets
02 Aug 2021 //
FIERCEBIOTECH
Exicure Announces Upcoming Neuroscience Pipeline Update at Virtual R&D Day
07 Jul 2021 //
BUSINESSWIRE
Exicure Reports First Quarter 2021 Financial Results and Corporate Progress
12 May 2021 //
BUSINESSWIRE
Exicure Granted Orphan Drug Designation by the U.S. FDA for Cavrotolimod
03 Mar 2021 //
BUSINESSWIRE
Exicure Granted Two Fast Track Designations for Cavrotolimod (AST-008)
11 Jan 2021 //
BUSINESSWIRE
Exicure Provides Neuroscience Pipeline Update at Virtual R&D Day
28 Dec 2020 //
BUSINESSWIRE
Exicure Provides Neuroscience Pipeline Update at Virtual R&D Day
28 Dec 2020 //
BUSINESSWIRE
Exicure Announces Issuance of Two New U.S. Patents and A New Patent Allowance
21 Dec 2020 //
BUSINESSWIRE
Exicure Announces Issuance of Two New U.S. Patents and A New Patent Allowance
21 Dec 2020 //
BIOSPACE
Exicure Presents Positive Clinical Data with Cavrotolimod at (SITC)
09 Nov 2020 //
BIOSPACE
Exicure Presents Positive Clinical Data with Cavrotolimod at (SITC)
09 Nov 2020 //
BUSINESSWIRE
Exicure Announces Phase 1b Poster Presentation at (SITC) 35th
19 Oct 2020 //
BUSINESSWIRE
Exicure Announces Phase 1b Poster Presentation at The (SITC)
19 Oct 2020 //
BUSINESSWIRE
Exicure to Present at the Chardan Virtual 4th Annual Genetic Medicines
05 Oct 2020 //
BUSINESSWIRE
Exicure Secures Debt Facility for Up to $25.0 Million
01 Oct 2020 //
BUSINESSWIRE
Exicure Presents Results from Ongoing Phase 1b/2 Trial of Cavrotolimod
16 Sep 2020 //
BUSINESSWIRE
Exicure Announces a Virtual KOL Meeting to Discuss Preliminary Phase 1b Efficacy
25 Aug 2020 //
BUSINESSWIRE
Exicure Presents Cavrotolimod (AST-008) Clinical Data at AACR 2020
22 Jun 2020 //
BUSINESSWIRE
Exicure Announces First Patient Dosed in Ph2 Cavrotolimod (AST-008)
17 Jun 2020 //
BIOSPACE
Exicure Announces First Dosed in Ph2 Merkel Cell Trial of Cavrotolimod (AST-008)
16 Jun 2020 //
PRESS RELEASE
Exicure Announces First Patient Dosed in Ph 2 Merkel Cell Carcinoma (AST-008)
16 Jun 2020 //
BUSINESSWIRE
Exicure to Present Clinical Data at AACR 2020 Virtual Meeting
15 May 2020 //
BUSINESSWIRE
Exicure to Present AST-008 Updates at 2020 AACR Virtual Annual Meeting
05 May 2020 //
BUSINESSWIRE
Exicure Announces First Neurological Development Program
16 Dec 2019 //
BUSINESS WIRE
